Uncovering the anti-cancer mechanisms of Immuno-Oncology

GNTbm-TKI is a potent selective inhibitor of multiple tyrosine kinases including TYRO3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2. It has strong immune-regulatory activity and can effectively inhibit tumor growth, tumor metastasis and invasion, tumor angiogenesis, and exert strong immune-regulatory effects through its multiple kinase inhibition mechanism. GNTbm-TKI can be used monotherapy for the treatment of neuroendocrine tumors.

GNTbm-TKI, through its unique activities of both immune activation and multi-target kinase inhibition, can be combined with GNTbm-38 to remodel the TME, attracting CTL infiltration into the TME for selectively attacking tumors, and preventing Immunosuppressive cells from being attracted to the TME. This potent tumor immune toxic can generate lasting immune memory, benefiting long-lasting non-recurrence in anti-cancer effects. On the other hand, combination of GNTbm-TKI plus GNTbm-38 with a anti-PD-1/VEGF bispecific antibody will provide excellent cancer immune treatment benefits, transforming 'cold tumors' into 'hot tumors.' This synergistic effect of multiple different drug mechanisms not only greatly remodels the TME but also activates CTLs for persistent attacks on tumors, significantly enhancing the effectiveness of cancer immunotherapy, broadening the treatment options for various solid tumors classified as cold tumors.